Our data indicate that pharmacological inhibition of eEF2K could represent a novel therapeutic intervention for treating epilepsy and related comorbidities in the Dravet syndrome. This evidence concerns the gene EEF2K and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.